Literature DB >> 30390820

Conventional Treatment of Hypoparathyroidism.

Muriel Babey1, Maria-Luisa Brandi2, Dolores Shoback3.   

Abstract

Conventional therapy of hypoparathyroidism consists of oral calcium and either activated vitamin D or vitamin D supplements at varying doses. Although adjusting dosing of calcium and/or activated vitamin D or vitamin D itself, the serum calcium should be obtained weekly or monthly depending on the clinical situation. Calcium supplementation in hypoparathyroidism usually consists of calcium carbonate because it is 40% elemental calcium by weight. However, calcium citrate (21% elemental calcium) is indicated for patients with achlorhydria and proton pump inhibitor therapy. Many clinicians prefer to uptitrate the activated form of vitamin D to reduce the amount of calcium supplementation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcitriol; Hypocalcemia; Hypoparathyroidism; PTH; Serum calcium; Serum phosphate

Mesh:

Substances:

Year:  2018        PMID: 30390820     DOI: 10.1016/j.ecl.2018.07.012

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

2.  Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.

Authors:  Markus Ketteler; Kristina Chen; Elvira O Gosmanova; James Signorovitch; Fan Mu; Joshua A Young; Nicole Sherry; Lars Rejnmark
Journal:  Adv Ther       Date:  2021-03-11       Impact factor: 3.845

Review 3.  Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review : Renal disease in chronic hypoparathyroidism.

Authors:  Elvira O Gosmanova; Pascal Houillier; Lars Rejnmark; Claudio Marelli; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2021-02-18       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.